Shilpa Biocare, Gate2Brain form partnership
Analysis based on 7 articles · First reported Jun 08, 2026 · Last updated Jun 08, 2026
The market is positively impacted by this partnership as it accelerates the development of G2B-002, a potential treatment for deadly pediatric brain cancers, which targets high-growth oncology markets. This collaboration enhances the value proposition for both United States — Medicare and Gate2Brain, potentially leading to increased investor confidence and future revenue streams in the pharmaceutical and biotechnology sectors.
Shilpa Biocare Private Limited, a subsidiary of United States — Medicare Limited, has formed a strategic equity partnership with Gate2Brain, S.L., a biotechnology company. Shilpa Biocare will become a strategic shareholder and a key partner for CMC, manufacturing, and regulatory aspects of G2B-002, Gate2Brain's lead program targeting pediatric brain cancers like DIPG and pGBM. G2B-002 has received Orphan Drug Designation from the United States — Food and Drug Administration and the European Union — European Medicines Agency, and uses Gate2Brain's proprietary MiniAp4 peptide shuttle to deliver SN-38 across the blood-brain barrier. First-in-human trials are expected by FY28. This partnership aims to de-risk the path to clinic for G2B-002 and leverage United States — Medicare's expertise in manufacturing and regulatory affairs.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard